Enigma Biomedical Group (EBG) has signed a Memorandum of Understanding to license Yale’s Synaptic Density Imaging (SDI) biomarker technology platform.
With this license, EBG will be responsible for the global development and commercialization of Yale’s early stage investigational imaging agents using Positron Emission Tomography (PET) to assess neurodegeneration. SDI promises to provide an important new tool in understanding neurodegenerative diseases such as Alzheimer’s and other dementias.
As part of the agreement, EBG will be responsible for the clinical development and commercialization of these SDI agents in return for payment of license fees, milestone payments and royalties on worldwide sales of any future products. EBG, and its partner, Cerveau Technologies, Inc., will work with their collective pharmaceutical industry partners to apply this technology together with the development of therapies expected to impact the progression of neurodegenerative diseases.
Lee Ann Gibbs, president of Enigma Biomedical Group, said, “This is an important step in accelerating critical biomarker research projects globally. Licensing the Yale technology platform allows Enigma, and its partner, Cerveau Technologies Inc., to continue to execute the collective strategy of providing biomarkers to industry and academia to accelerate research in the field of neurodegenerative diseases.”
“We are pleased to collaborate with Enigma Biomedical Group to further develop and validate this technology in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as other neurologic disorders.” said Dr. Yiyun Henry Huang, Professor, Department of Radiology and Biomedical Imaging, and Director of Chemistry and Co-Director, Yale PET Center.